Guidance

Mpox vaccine PGD template (previously named smallpox vaccine PGD)

PGD template for administering mpox vaccine in response to mpox (monkeypox).

From:
UK Health Security Agency
Published
5 August 2022
Last updated
14 October 2024 鈥� See all updates

Applies to England

Documents

Ref: UKHSA gateway number GOV-17181

MS Word Document, 195 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This mpox patient group direction (PGD) template (previously known as smallpox vaccine PGD) supports the administration of the mpox vaccine, modified vaccina virus Ankara-Bavarian Nordic (MVA-BN), to individuals identified for immunisation in response to mpox incidents and routine vaccination ( see JCVI recommendations 10 November 2023).

The mpox PGD version 4.00 is valid from 10 October 2024 to 30 April 2027.

Practitioners must not use this聽PGD聽template until it has been authorised in Section 2. This is a legal requirement (see聽). Practitioners should follow local policy/procedures to access authorised聽PGD听诲辞肠耻尘别苍迟蝉.

罢丑颈蝉听PGD聽template should be used with reference to current national guidance, the聽Green Book, and聽聽for the vaccine.

Updates to this page

Published 5 August 2022
Last updated 14 October 2024 show all updates

  1. Added mpox PGD version 4 - see page 3 for change history.

  2. Added 'Notice of extension of the validity of smallpox vaccine PGD'.

  3. Added version 3 - see page 2 for change history.

  4. Added version 2.00 鈥� details of changes on page 2 and updated batch information.

  5. Corrected review date.

  6. First published.

Sign up for emails or print this page

Related content